| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

29 March 2021

ORYZON enrolls first patient in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder

24 March 2021

ORYZON publishes vafidemstat first-in-human clinical trial manuscript in CNS Drugs journal

13 April 2021

Business Roundtable on Health, Pharmas and Hospitals

28-30 April 2021

4th SACHS Annual Neuroscience Innovation Forum 2021

21 April 2021

Kempen Life Sciences Conference

22-25 March 2021

BIO-Europe Spring 2021

18 March 2021

ORYZON to participate in upcoming virtual international conferences in March and April

15 March 2021

ORYZON announces successful pre-IND meeting with FDA for the clinical development of vafidemstat in Borderline Personality Disorder

9 March 2021

ORYZON presents vafidemstat 12-month clinical data from its Phase IIa clinical trials ETHERAL and REIMAGINE-AD in Alzheimer’s at the virtual AD/PD-2021 conference

22 February 2021

ORYZON reports results and corporate update for 4th quarter and year ended December 31, 2020

Pagination

First page «
Previous page ‹
Page 23
Page 24
Page 25
Page 26
Current page 27
Page 28
Page 29
Page 30
Page 31
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel